Drug Trial Radar · NCT07726342
SMP-656 for HER2-Positive Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Aug 10, 2026
Primary completion
Jul 7, 2027
Study completion Oct 20, 2027
Sponsor
- Lead sponsor
- Chengdu SciMount Pharmatech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if single-agent SMP-656 works to treat patients with HER2-positive locally advanced or metastatic breast cancer who have progressed after prior HER2-targeted topoisomerase inhibitor antibody-drug conjugate (ADC) treatment. It will also evaluate the safety of SMP-656 and identify the optimal dose for future trials. The main questions it aims to answer are: What is the objective tumor response rate (DOR, PFS, DCR, OS) of two different dose regimens of intravenous SMP-656? What are the side effects and safety risks of these two SMP-656 dose regimens? Which dose level achieves the best balance of anti-cancer activity and tolerability? This is a randomized, open-label, dose-optimization Phase II clinical trial. Participants will be randomly assigned 1:1 to receive one of two fixed doses of SMP-656 given intravenously once every 3 weeks. Participants will: Complete screening tests within 28 days before the first SMP-656 infusion to confirm eligibility Receive study treatment every 3 weeks until cancer progression, intolerable side effects, withdrawal, or other stopping criteria Have regular tumor imaging scans, physical exams, vital sign checks, and blood tests to monitor tumor response and safety Attend a safety follow-up visit 30 days after the last dose of SMP-656 Complete longer-term survival follow-up after the 30-day safety check Provide optional blood and tumor tissue samples for additional research studies
Conditions
- HER2-positive Breast Cancer
- Metastatic Breast Cancer
- Locally Advanced Breast Cancer (LABC)
Interventions
SMP-656 InjectionDrug
SMP-656 injection administered via intravenous infusion at a dose of 2.0 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.
SMP-656 InjectionDrug
SMP-656 injection administered via intravenous infusion at a dose of 2.2 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) assessed by Independent Review Committee (IRC)Time frame: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
- Recommended Dose in Pivotal Clinical TrialsTime frame: Through study completion, up to 24 months from first dose
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Not yet recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Not yet recruiting
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, China · Not yet recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
Changsha, Hunan, China · Not yet recruiting
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, China · Not yet recruiting
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China · Not yet recruiting
Shandong Cancer Hospital and Institute
Jinan, Shandong, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China · Not yet recruiting
Sichuan Cancer Hospital & Institute
Chengdu, Sichuan, China · Not yet recruiting
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.